Dermatologic Manifestations of Zika Virus (DMZV)

January 31, 2019 updated by: Roopal Kundu, Northwestern University

Survey of Symptoms and Dermatologic Characterization Associated With Zika Virus

The purpose of this study is to determine whether any diagnostic patterns exist in the symptom presentation of Zika Virus.

Study Overview

Status

Withdrawn

Conditions

Intervention / Treatment

Detailed Description

The study has both retrospective and prospective components. The retrospective review includes medical records with laboratory confirmed Zika Virus diagnosis and the prospective component will enroll adults presenting with febrile illness and rash and ask them to complete a survey about their symptoms. Diagnostic testing will be completed to confirm infection source.

Study Type

Observational

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Dominican Republic
    • Illinois
      • Santo Domingo, Illinois, Dominican Republic
        • Pontificia Universidad Catolica Madre y Maestra, Departamento de Medicina

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Adults 18 y/o with confirmed zika virus diagnosis

Description

Inclusion Criteria:

  • Adults aged 18 years and older presenting with febrile illness and rash

Exclusion Criteria:

  • Patients aged 17 years or younger

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of days with specific symptoms
Time Frame: 20 minutes
Number of days reported experiencing specific symptoms due to Zika Virus infection and and associated characteristics such as location and intensity
20 minutes

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Frequency measures of initial clinical presentations
Time Frame: 20 minutes
Frequency of reported symptoms at initial clinical presentation.
20 minutes

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Northwestern University

Collaborators

Pontificia Universidad Catolica Madre y Maestra

Investigators

  • Principal Investigator: Roopal V. Kundu, MD, Northwestern University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 6, 2017

Primary Completion (Actual)

December 31, 2018

Study Completion (Actual)

December 31, 2018

Study Registration Dates

First Submitted

July 18, 2017

First Submitted That Met QC Criteria

July 21, 2017

First Posted (Actual)

July 25, 2017

Study Record Updates

Last Update Posted (Actual)

February 4, 2019

Last Update Submitted That Met QC Criteria

January 31, 2019

Last Verified

January 1, 2019

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • STU00205325

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Zika Virus Symptoms and the Associated Exanthema

Clinical Trials on Survey

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Spain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe